Symbols / PLX $1.91 -1.55% Protalix BioTherapeutics, Inc.

Healthcare • Biotechnology • United States • ASE
PLX Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Dror Bashan
Exch · Country ASE · United States
Market Cap 153.89M
Enterprise Value 131.94M
Income -6.60M
Sales 52.74M
FCF (ttm) -12.20M
Book/sh 0.60
Cash/sh 0.38
Employees 226
Insider 10d —
IPO May 15, 1998
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 26.75
Forward P/E 3.08
PEG —
P/S 2.92
P/B 3.18
P/C —
EV/EBITDA -32.70
EV/Sales 2.50
Quick Ratio 1.50
Current Ratio 2.51
Debt/Eq 17.25
LT Debt/Eq —
EPS (ttm) -0.08
EPS next Y 0.62
EPS Growth —
Revenue Growth -49.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-18
ROA -4.41%
ROE -14.44%
ROIC —
Gross Margin 13.01%
Oper. Margin -51.06%
Profit Margin -12.52%
Shs Outstand 80.57M
Shs Float 72.73M
Insider Own 3.88%
Instit Own 24.06%
Short Float 6.12%
Short Ratio 4.83
Short Interest 4.73M
52W High 3.19
vs 52W High -40.13%
52W Low 1.32
vs 52W Low 44.70%
Beta -0.01
Impl. Vol. 1.63%
Rel Volume 0.60
Avg Volume 980.14K
Volume 590.91K
Target (mean) $11.00
Tgt Median $11.00
Tgt Low $10.00
Tgt High $12.00
# Analysts 2
Recom None
Prev Close $1.94
Price $1.91
Change -1.55%
About

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.00
Mean price target
2. Current target
$1.91
Latest analyst target
3. DCF / Fair value
$-2.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.91
Low
$10.00
High
$12.00
Mean
$11.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-19 reit HC Wainwright & Co. Buy → Buy $12
2025-11-21 main HC Wainwright & Co. Buy → Buy $12
2025-02-03 main HC Wainwright & Co. Buy → Buy $15
2023-11-14 reit HC Wainwright & Co. Buy → Buy $10
2023-10-31 main HC Wainwright & Co. Buy → Buy $10
News
RSS: Latest PLX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-19 BASHAN DROR Chief Executive Officer — 56,000 $1.81 $101,360
2025-11-18 BAR SHALEV AMOS Director — 168 $1.87 $314
2025-09-03 MELINCOFF GWEN A Director — 7,500 $0.00 $0
2025-09-03 BAR SHALEV AMOS Director — 7,500 $0.00 $0
2025-09-03 BOUDES POL F Director — 7,500 $0.00 $0
2025-09-03 SCHWARTZ AHARON Director — 7,500 $0.00 $0
2025-09-03 NAOS YARON Officer — 25,000 $0.00 $0
2025-09-03 BASHAN DROR Chief Executive Officer — 195,000 $0.00 $0
2025-09-03 FORSTER ELIOT Director — 7,500 $0.00 $0
2025-09-03 BEN ZVI SHMUEL Director — 7,500 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
52.74
-1.23%
53.40
-18.47%
65.49
+37.48%
47.64
Operating Revenue
52.74
-1.23%
53.40
-18.47%
65.49
+37.48%
47.64
Cost Of Revenue
26.99
+11.00%
24.32
+5.82%
22.98
+17.30%
19.59
Reconciled Cost Of Revenue
26.99
+11.00%
24.32
+5.82%
22.98
+17.30%
19.59
Gross Profit
25.75
-11.45%
29.08
-31.60%
42.51
+51.58%
28.05
Operating Expense
31.25
+24.19%
25.16
-21.49%
32.05
-21.94%
41.06
Research And Development
19.57
+50.88%
12.97
-24.12%
17.09
-41.76%
29.35
Selling General And Administration
11.68
-4.19%
12.19
-18.49%
14.96
+27.73%
11.71
Total Expenses
58.24
+17.71%
49.48
-10.09%
55.03
-9.26%
60.65
Operating Income
-5.50
-240.41%
3.92
-62.55%
10.46
+180.37%
-13.01
Total Operating Income As Reported
-5.50
-240.41%
3.92
-62.55%
10.46
+180.37%
-13.01
EBITDA
-2.95
-145.28%
6.52
-49.60%
12.94
+219.99%
-10.78
Normalized EBITDA
-2.95
-145.28%
6.52
-49.60%
12.94
+219.99%
-10.78
Reconciled Depreciation
1.47
+12.35%
1.30
+9.49%
1.19
+9.67%
1.09
EBIT
-4.42
-184.68%
5.22
-55.59%
11.75
+198.97%
-11.87
Net Income
-6.60
-325.24%
2.93
-64.73%
8.31
+155.68%
-14.93
Pretax Income
-5.61
-235.00%
4.15
-51.51%
8.57
+159.50%
-14.40
Net Non Operating Interest Income Expense
-0.11
-145.57%
0.24
+112.51%
-1.89
-36.95%
-1.38
Interest Expense Non Operating
1.19
+12.15%
1.06
-66.60%
3.18
+25.74%
2.53
Net Interest Income
-0.11
-145.57%
0.24
+112.51%
-1.89
-36.95%
-1.38
Interest Expense
1.19
+12.15%
1.06
-66.60%
3.18
+25.74%
2.53
Interest Income Non Operating
1.08
-16.63%
1.30
+1.01%
1.29
+12.22%
1.15
Interest Income
1.08
-16.63%
1.30
+1.01%
1.29
+12.22%
1.15
Tax Provision
1.00
-18.49%
1.22
+381.10%
0.25
-52.08%
0.53
Tax Rate For Calcs
0.00
-28.61%
0.00
+892.09%
0.00
-25.87%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-6.60
-325.24%
2.93
-64.73%
8.31
+155.68%
-14.93
Net Income From Continuing Operation Net Minority Interest
-6.60
-325.24%
2.93
-64.73%
8.31
+155.68%
-14.93
Net Income From Continuing And Discontinued Operation
-6.60
-325.24%
2.93
-64.73%
8.31
+155.68%
-14.93
Net Income Continuous Operations
-6.60
-325.24%
2.93
-64.73%
8.31
+155.68%
-14.93
Normalized Income
-6.60
-325.24%
2.93
-64.73%
8.31
+155.68%
-14.93
Net Income Common Stockholders
-6.60
-325.24%
2.93
-64.73%
8.31
+155.68%
-14.93
Diluted EPS
-0.08
-300.00%
0.04
-55.56%
0.09
+129.03%
-0.31
Basic EPS
-0.08
-300.00%
0.04
-66.67%
0.12
+138.71%
-0.31
Basic Average Shares
78.55
+8.29%
72.53
+7.43%
67.51
+39.28%
48.47
Diluted Average Shares
78.55
-3.10%
81.06
-1.66%
82.42
+70.04%
48.47
Diluted NI Availto Com Stockholders
-6.60
-325.24%
2.93
-64.73%
8.31
+155.68%
-14.93
Line Item Trend 2023-12-31
Total Assets
84.43
Current Assets
69.93
Cash Cash Equivalents And Short Term Investments
44.56
Cash And Cash Equivalents
23.63
Other Short Term Investments
20.93
Receivables
5.27
Accounts Receivable
5.27
Inventory
19.05
Raw Materials
4.18
Work In Process
9.05
Finished Goods
5.81
Prepaid Assets
0.44
Restricted Cash
—
Other Current Assets
0.61
Total Non Current Assets
14.50
Net PPE
10.88
Gross PPE
45.57
Accumulated Depreciation
-34.69
Properties
0.00
Machinery Furniture Equipment
3.08
Other Properties
24.84
Leases
17.64
Non Current Deferred Assets
3.09
Non Current Deferred Taxes Assets
3.09
Total Liabilities Net Minority Interest
50.87
Current Liabilities
45.53
Payables And Accrued Expenses
22.27
Payables
7.83
Accounts Payable
4.32
Other Payable
0.64
Current Accrued Expenses
14.43
Employee Benefits
0.71
Pensionand Other Post Retirement Benefit Plans Current
1.60
Total Tax Payable
2.88
Income Tax Payable
2.88
Current Debt And Capital Lease Obligation
21.66
Current Debt
20.25
Other Current Borrowings
20.25
Current Capital Lease Obligation
1.41
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Total Non Current Liabilities Net Minority Interest
5.33
Long Term Debt And Capital Lease Obligation
4.62
Long Term Debt
—
Long Term Capital Lease Obligation
4.62
Defined Pension Benefit
0.53
Non Current Pension And Other Postretirement Benefit Plans
0.71
Non Current Deferred Liabilities
—
Non Current Deferred Revenue
—
Stockholders Equity
33.57
Common Stock Equity
33.57
Capital Stock
0.07
Common Stock
0.07
Share Issued
72.95
Ordinary Shares Number
72.95
Treasury Shares Number
0.00
Additional Paid In Capital
415.05
Retained Earnings
-381.55
Total Equity Gross Minority Interest
33.57
Total Capitalization
33.57
Working Capital
24.40
Invested Capital
53.82
Total Debt
26.28
Net Debt
—
Capital Lease Obligations
6.03
Net Tangible Assets
33.57
Tangible Book Value
33.57
Current Notes Payable
—
Current Provisions
—
Interest Payable
0.51
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-11.99
-238.26%
8.67
+758.12%
-1.32
+94.73%
-25.00
Cash Flow From Continuing Operating Activities
-11.99
-238.26%
8.67
+758.12%
-1.32
+94.73%
-25.00
Net Income From Continuing Operations
-6.60
-325.24%
2.93
-64.73%
8.31
+155.68%
-14.93
Depreciation Amortization Depletion
1.47
+12.35%
1.30
+9.49%
1.19
+9.67%
1.09
Depreciation
1.47
+12.35%
1.30
+9.49%
1.19
+9.67%
1.09
Depreciation And Amortization
1.47
+12.35%
1.30
+9.49%
1.19
+9.67%
1.09
Other Non Cash Items
0.61
+95.48%
0.31
+151.67%
-0.60
+12.92%
-0.69
Pension And Employee Benefit Expense
0.00
+101.18%
-0.17
-259.57%
-0.05
+91.30%
-0.54
Stock Based Compensation
2.30
-29.39%
3.25
-5.66%
3.45
+65.37%
2.08
Deferred Tax
0.34
+44.07%
0.24
+107.63%
-3.09
0.00
Deferred Income Tax
0.34
+44.07%
0.24
+107.63%
-3.09
0.00
Operating Gains Losses
0.00
+101.16%
-0.17
-352.63%
-0.04
+92.96%
-0.54
Gain Loss On Sale Of PPE
0.00
+100.00%
-0.00
-133.33%
0.01
0.00
Change In Working Capital
-10.10
-1345.25%
0.81
+107.70%
-10.54
+12.28%
-12.02
Change In Receivables
-5.89
-354.21%
2.32
+641.36%
-0.43
+64.15%
-1.19
Changes In Account Receivables
-5.89
-354.21%
2.32
+641.36%
-0.43
+64.15%
-1.19
Change In Inventory
-4.49
-104.09%
-2.20
+1.92%
-2.24
-294.87%
1.15
Change In Payables And Accrued Expense
0.29
-58.05%
0.70
-86.86%
5.29
+210.22%
-4.80
Change In Other Working Capital
—
—
-13.18
-84.00%
-7.16
Change In Other Current Assets
-0.01
-275.00%
-0.00
-130.77%
0.01
+360.00%
-0.01
Change In Other Current Liabilities
—
—
0.00
0.00
Investing Cash Flow
-2.37
-156.05%
4.22
+125.26%
-16.71
-231.90%
-5.04
Cash Flow From Continuing Investing Activities
-2.37
-156.05%
4.22
+125.26%
-16.71
-231.90%
-5.04
Net PPE Purchase And Sale
-1.64
-28.07%
-1.28
-11.31%
-1.15
-82.96%
-0.63
Purchase Of PPE
-1.64
-27.77%
-1.28
-11.58%
-1.15
-82.96%
-0.63
Sale Of PPE
0.00
-100.00%
0.00
0.00
0.00
Capital Expenditure
-1.64
-27.77%
-1.28
-11.58%
-1.15
-82.96%
-0.63
Net Investment Purchase And Sale
0.00
-100.00%
5.42
+135.15%
-15.42
-208.40%
-5.00
Purchase Of Investment
-5.00
+66.67%
-15.00
+26.54%
-20.42
-27.63%
-16.00
Sale Of Investment
5.00
-75.51%
20.42
+308.40%
5.00
-54.55%
11.00
Net Other Investing Changes
-0.73
-1010.00%
0.08
+156.34%
-0.14
-123.95%
0.59
Financing Cash Flow
9.33
+155.53%
-16.79
-168.09%
24.67
+199.42%
8.24
Cash Flow From Continuing Financing Activities
9.33
+155.53%
-16.79
-168.09%
24.67
+199.42%
8.24
Net Issuance Payments Of Debt
0.00
+100.00%
-20.42
0.00
0.00
Repayment Of Debt
0.00
+100.00%
-20.42
0.00
0.00
Long Term Debt Payments
—
—
0.00
0.00
Net Long Term Debt Issuance
—
—
0.00
0.00
Short Term Debt Payments
0.00
+100.00%
-20.42
0.00
0.00
Net Short Term Debt Issuance
0.00
+100.00%
-20.42
0.00
0.00
Net Common Stock Issuance
6.81
+87.87%
3.63
-84.86%
23.95
+190.85%
8.24
Proceeds From Stock Option Exercised
2.51
0.00
-100.00%
0.71
+35500.00%
0.00
Changes In Cash
-5.03
-29.08%
-3.90
-158.75%
6.64
+130.45%
-21.80
Effect Of Exchange Rate Changes
-0.05
-288.00%
0.03
+121.93%
-0.11
-48.05%
-0.08
Beginning Cash Position
19.76
-16.39%
23.63
+38.12%
17.11
-56.11%
38.98
End Cash Position
14.68
-25.71%
19.76
-16.39%
23.63
+38.12%
17.11
Free Cash Flow
-13.63
-284.40%
7.39
+399.64%
-2.47
+90.37%
-25.63
Interest Paid Supplemental Data
—
—
—
—
Common Stock Issuance
6.81
+87.87%
3.63
-84.86%
23.95
+190.85%
8.24
Issuance Of Capital Stock
6.81
+87.87%
3.63
-84.86%
23.95
+190.85%
8.24
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category